{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0008283",
      "entity_text" : "proliferation",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P01116",
      "entity_text" : "KRAS",
      "entity_type" : "protein"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "We hypothesize that through an optimized MEKi dosing schedule, we can maximize the suppression of KRAS induced proliferation and survival of cancer cells while minimizing the detrimental effects on immune cells.",
  "reading_complete" : "2020-08-08T10:51:41Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T10:49:20Z",
  "trigger" : "induced",
  "evidence" : [ "KRAS-induced proliferation" ],
  "pmc_id" : "6719696",
  "score" : 0
}